3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Neoplasms, Plasma Cell
1
Neoplasms
1
Lymphoma
1
Leukemia
1
Infections
1
Hematologic Neoplasms
1
Agammaglobulinemia
1
Interventions
Trimethoprim, Sulfamethoxazole Drug Combination
7
Ciprofloxacin
5
gamma-Globulins
3
Amoxicillin-Potassium Clavulanate Combination
3
liposomal amphotericin B
2
Trimethoprim
2
Sulfamethoxazole
2
Peripheral Blood Stem Cell Transplantation
2
Pentetic Acid
2
Moxifloxacin
2
Melphalan
2
Itraconazole
2
Immunoglobulins, Intravenous
2
Cyclophosphamide
2
Caspofungin
2
talquetamab
1
idecabtagene vicleucel
1
fludarabine phosphate
1
ethanolamine oleate
1
amphotericin B, deoxycholate drug combination
1
Whole-Body Irradiation
1
Watchful Waiting
1
Voriconazole
1
Vancomycin
1
Valacyclovir
1
Therapeutics
1
Tazobactam
1
Tacrolimus
1
Sodium Chloride
1
Sirolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Infections
×
Clavulanic Acid
×
Plasma cell
×
Clear all
NCT05678621
2024-04-19
RATIONALISE
Monash University
Phase 2/3
Recruiting
300 enrolled